NRx Pharmaceuticals publishes shareholder update letter

NRx Pharmaceuticals announced that the Company posted a new Shareholder Update Letter. ‘The first half of 2024 has been both productive and challenging for us… The questions most frequently asked relate to our financial path forward, particularly in light of recent clinical trial data, the cancellation of our development agreement with Alvogen, and our dispute with Streeterville. The key question for NRx, in management’s opinion, is: “How does NRx become a profitable biotechnology company in 2025?”… In our view, we have three viable paths to significant revenue beginning in 2024 with a potential for profitability by the end of 2025 that will not require investing in an additional clinical trial: Revenue from operation of HOPE Therapeutics-branded interventional psychiatry clinics, Revenue from sales of NRX-100 based on an FDA New Drug Application approval, and Revenue from sales of NRX-101 as an FDA-approved product for the sub-population of people with suicidal bipolar depression and akathisia. These are opportunities that the Company can pursue with currently-available financial resources… Given the Company’s current market capitalization, we believe that success in any one of the first three opportunities is consistent with a sizeable increase in our share value, consistent with published projections by public markets securities analysts… 1. Commercial Development of Ketamine Clinics… 2. Approval and marketing of NRX-100/HTX-100 for suicidal depression… 3. Approval and marketing of NRX-101 for patients with suicidal bipolar depression and akathisia”